

**2018 Mo-99 Topical Meeting on
Molybdenum-99 Production Technology Development**

**September 23-26, 2018
Hilton Knoxville Hotel
Knoxville, TN**

BWXT Breakthrough Medical Isotope Technology

T.R. Burnett

BWXT Isotope Technologies,
447 March Road, Kanata, ON K2K 1X8, Canada

ABSTRACT

BWXT is a leading supplier of nuclear components and fuel to the U.S. government; provides technical and management services to support the U.S. government in the operation of complex facilities and environmental remediation activities; and supplies precision manufactured components, services and fuel for the commercial nuclear power industry. BWXT recently announced its entry into the medical isotope and radiopharmaceutical industry and has developed an innovative and unique process to manufacture molybdenum-99 (Mo-99) and technetium-99m (Tc-99m) generators that will enable a new, stable supply of this critical diagnostic medical isotope. To derisk BWXT's entry into the medical radioisotope market, BWXT has acquired Sotera Health's Nordion medical isotope business including the licensed infrastructure, approximately 150 highly trained and experienced personnel and two North American-based production centers. To enable long-term, stable and reliable supply, BWXT is collaborating with Ontario Power Generation's (OPG) subsidiary Canadian Nuclear Partners (CNP) for irradiation services. This collaboration is expected to make Darlington Nuclear the first large-scale commercial nuclear power station worldwide to irradiate targets producing Mo-99.